Our results indicate that ∼1/3 of melanoma patients (nearly all of them early stage) have significantly elevated levels of MLANA and MIF marker RNAs compared with healthy volunteers, and similar results have been reported in a number of other studies [12], [14], [29], [30]. This evidence concerns the gene MLANA and melanoma.